Abstract
Two reports demonstrate how new chemical probes for amyloid-β deposits aids in the detection of Alzheimer disease (AD) in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hintersteiner, M. et al. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 23, 577–583 (2005).
Sato, K. et al. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur. J. Med. Chem. 39, 573–578 (2004).
Higuchi, M. et al. 19F and 1H MRI detection of amyloid-β plaques in vivo. Nat. Neurosci. 8, 527–533 (2005).
Rights and permissions
About this article
Cite this article
Evanko, D. Imaging Alzheimer disease: seeing the unseeable. Nat Methods 2, 481 (2005). https://doi.org/10.1038/nmeth0705-481
Issue date:
DOI: https://doi.org/10.1038/nmeth0705-481
